Liquidia Corporation (LQDA) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $38.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality.
Liquidia is a biopharmaceutical company developing inhaled therapies for pulmonary arterial hypertension and PH-ILD. Revenue comes from sales of YUTREPIA (FDA-approved May 2025) and a profit-sharing agreement with Sandoz for Treprostinil Injection in the US. The company carries... Read more
Sell if holding. Engine safety override at $38.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYUTREPIA10-K Item 1A: 'We are primarily dependent on the success of YUTREPIA, for which we recently received FDA approval for the treatment of PAH and PH-ILD'
- HIGHSupplierSandoz10-K Item 1A: 'Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection and is dependent on Sandoz to manufacture and supply Treprostinil Injection in compliance with FDA requirements'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $35.92. Score 4.5/10, moderate confidence.
Take-profit target: $44.08 (+14.1% upside). Prior stop was $35.92. Stop-loss: $35.92.
Concentration risk — Product: YUTREPIA; Concentration risk — Supplier: Sandoz; Risk below floor (2.7 < 3.0).
Liquidia Corporation trades at a P/E of N/A (forward 7.3). TrendMatrix value score: 5.1/10. Verdict: Sell.
15 analysts cover LQDA with a consensus score of 4.1/5. Average price target: $51.
What does Liquidia Corporation do?Liquidia is a biopharmaceutical company developing inhaled therapies for pulmonary arterial hypertension and PH-ILD....
Liquidia is a biopharmaceutical company developing inhaled therapies for pulmonary arterial hypertension and PH-ILD. Revenue comes from sales of YUTREPIA (FDA-approved May 2025) and a profit-sharing agreement with Sandoz for Treprostinil Injection in the US. The company carries an accumulated deficit of 626.3M and achieved partial profitability in Q3-Q4 2025.